Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04386005 · ClinicalTrials.gov registry record · NA

Continuous Glucose Monitoring in At-Risk Newborns

A NA study of Neonatal Hypoglycemia, sponsored by Milton S. Hershey Medical Center.

Recruiting
Registry status
NA
Development phase
100
Enrollment target
1
Study location

NCT04386005 is a NA study of Neonatal Hypoglycemia that is actively recruiting participants, run by Milton S. Hershey Medical Center. The registered enrollment target is 100 participants, below the 122-participant average among 5 other Neonatal Hypoglycemia trials with a reported enrollment target (18% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04386005, a NA study of Neonatal Hypoglycemia, is actively recruiting participants, sponsored by Milton S. Hershey Medical Center.

RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

Hypoglycemia (low blood glucose) is a very common problem in newborns, and has been associated with poor neurodevelopment, cognition, and school performance. At-risk newborns (infants of diabetic mothers \[IDM\], large \[LGA\] and small \[SGA\] for gestational age infants, and late preterm \[LPT\] infants) undergo a hypoglycemia screening protocol that involves numerous intermittent needle sticks to test glucose levels on bedside glucometers; however, continuous glucose monitoring (CGM, currently not approved for clinical use in babies), via a small sensor placed in the thigh (only 1 needle stick), would likely decrease pain while providing continuous glucose levels. This study will evaluate the feasibility, safety, and precision of CGM in at-risk newborns, and determine if this method would decrease the amount of painful procedures and episodes of hypoglycemia missed by intermittent sampling. As part of regular medical care, participants will undergo intermittent blood glucose screening with heel sticks as per the current hospital standard of care protocol. Regular medical care involves checking the participant's blood glucose via heel stick every few hours using a bedside glucometer, with another heel stick to confirm low values in the laboratory. If the participant has low values, he/she may be treated with oral glucose gel, feedings of breast milk or formula, or intravenous (IV) fluids in the Neonatal Intensive Care Unit (NICU). This research study involves placing a CGM device in addition to undergoing the current blood glucose screening protocol and treatment. As soon as possible after birth, a continuous glucose monitoring device (Dexcom G7) will be placed on the participant's thigh by a research team member, and will blindly continuously record glucose levels that will be analyzed after discharge. Everyone who agrees to participate in this study will have placement of this experimental device. The investigational device will stay in place for the same amo

Conditions Studied

Interventions

  • DEVICE Continuous Glucose Monitoring Device

Study Locations (1)

Pennsylvania

  • Penn State Health Milton S Hershey Medical Center - Hershey

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2021-08-09
Est. Completion 2026-06
Phase NA

Sponsor

Milton S. Hershey Medical Center

396 total trials

What the Registry Record Tells You About NCT04386005

The ClinicalTrials.gov registry entry for NCT04386005 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 122-participant average among 5 other Neonatal Hypoglycemia trials with a reported enrollment target (18% lower). The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neonatal Hypoglycemia appearing as the primary indexed condition, and to 1 intervention - of which Continuous Glucose Monitoring Device is the first listed.

NCT04386005 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT04386005 about?

NCT04386005 is a clinical study titled "Continuous Glucose Monitoring in At-Risk Newborns". Hypoglycemia (low blood glucose) is a very common problem in newborns, and has been associated with poor neurodevelopment, cognition, and school performance. At-risk newborns (infants of diabetic mothers \[IDM\], large \[LGA\] and small \[SGA\] for gestational age infants, and late preterm \[LPT\] i...

What is the current status of trial NCT04386005?

This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2021-08-09. Estimated completion is 2026-06.

What conditions does trial NCT04386005 study?

This clinical trial studies the following conditions: Neonatal Hypoglycemia.

What interventions are being tested in trial NCT04386005?

The interventions under investigation include: Continuous Glucose Monitoring Device (DEVICE).

Who is sponsoring clinical trial NCT04386005?

This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04386005 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Neonatal Hypoglycemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.